Shanghai Eye Disease Prevention and Treatment Center
Phase
Not applicable
Started
2024-03-11
Last updated
2025-04-24
Condition(s) studied
Epiretinal Membrane
Investigational drug(s) / intervention(s)
vitrectomy combined with intravitreal dexamethasone implant
vitrectomy combined with intravitreal dexamethasone implant: The dexamethasone implant will be injected into the vitreous cavity at the end of the surgery.
Study summary
The goal of this clinical trial is to evaluate the efficacy and safety of 25-gauge pars plana vitrectomy combined with intravitreal dexamethasone implant for the treatment of idiopathic epiretinal membrane with cystoid macular oedema. The main questions it aims to answer are:
* mean changes in best corrected visual acuity and central macular thickness from baseline to post-operative 24 weeks
* mean change in proportion of cystoid macular oedema area from baseline to post-operative 24 weeks
* intraocular pressure throughout postoperative 24 weeks
* concentrations of inflammatory factors in vitreous samples Participants will undergo a standard three-port 25-gauge pars plana vitrectomy and epiretinal membrane peeling combined with phacoemulsification, aspiration, and intraocular lens implantation. The dexamethasone implant will be injected into the vitreous cavity at the end of the operation.
Eligibility
Sex
ALL
Min age
40 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* symptomatic patients aged 40 years or above with idiopathic stage 3-4 epiretinal membrane defined on the basis of spectral-domain optical coherence tomography classification;
* central retinal thickness \>300 µm;
* cystoid oedema within a 1 mm diameter range with the macular fovea as the center;
* ocular axial length less than 25.00 mm.
Exclusion Criteria:
* concomitant or previous macular diseases that may hinder visual improvement other than epiretinal membrane (e.g., age-associated macular degeneration, retinal vein occlusion, or diabetic macular oedema);
* previous vitreoretinal surgery or intravitreal injection history;
* history of glaucoma or optic neuropathy of any kind;
* patients with uncontrolled systemic diseases or infectious diseases;
* patients who took medicines that may have ocular side effects, such as glucocorticoid or hydroxychloroquine.
Primary outcome measure(s)
improvement of visual acuity — from baseline to postoperative 24 weeks mean change in best corrected visual acuity
Trial sites (1)
Facility
City
Region
Status
Shanghai Eye Disease Prevention & Treatment Center
Shanghai
Shanghai Municipality
More Shanghai Eye Disease Prevention and Treatment Center trials in China
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.